Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route Gene Therapy for Friedreich’s Ataxia
Tuesday, December 02, 2025
Solid Biosciences has received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, its investigational gene therapy for Friedreich’s ataxia (FA). The therapy is designed to deliver the full-length frataxin gene through two routes: direct intradentate nucleus (IDN) infusion and intravenous (IV) administration. This dual approach aims to restore therapeutic levels of the frataxin protein to help address the neurological, cardiac, and systemic complications associated with FA.
The Rare Pediatric Disease designation supports the development of treatments for serious and life-threatening conditions that mainly affect children under 18 years of age. It also provides the potential for a priority review voucher (PRV), which can speed up the review of future Biologics License Applications. The voucher can be used by the company or sold to another organisation.
The designation adds to the Fast Track status granted earlier in the year, reflecting the importance of Solid’s dual-route clinical strategy in its first-in-human FALCON trial, which is now screening participants. These regulatory recognitions are intended to support faster development and closer interaction with the FDA.
SGT-212 is a recombinant AAV-based gene replacement therapy designed to deliver full-length human frataxin (FXN). It uses MRI-guided intradentate nucleus infusion, followed by IV administration, to raise FXN levels in the cerebellar dentate nuclei and in heart cells. The targeted delivery to the dentate nuclei will be monitored in real time using gadolinium, an MRI contrast agent. Increasing FXN levels is expected to help correct mitochondrial dysfunction in neurons and cardiomyocytes, which could improve neurological, cardiac, and systemic symptoms of FA.
Source: globenewswire.com
